Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.
Journal of Clinical Oncology1998Vol. 16(4), pp. 1425–1429
Citations Over TimeTop 10% of 1998 papers
Hubert Pehamberger, H. Peter Soyer, Andreas Steiner, Regina M. Kofler, Michael Binder, P Mischer, Wolf Pachinger, Josef Auböck, Peter Fritsch, H. Kerl, K. Wolff
Abstract
Adjuvant IFNalpha2a treatment diminishes the occurrence of metastases and thus prolongs disease-free survival in resected primary stage II cutaneous melanoma patients.
Related Papers
- → A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C(1994)284 cited
- → Pharmacokinetics and Tissue Distribution of Recombinant Human Alpha A, D, A/D(Bgl), and I Interferons and Mouse Alpha-Interferon in Mice(1986)26 cited
- Influence of interferon alfa-2b with or without folinic acid on pharmacokinetics of fluorouracil.(1992)
- → Therapy of hepatitis C: Interferon alfa-n1 trials(1997)47 cited
- Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer.(1992)